InnoCare Pharma (OTCMKTS:INCPF – Get Free Report) will likely be announcing its resultson Monday, August 24th. Analysts expect the company to post earnings of ($0.0126) per share and revenue of $101.70 million for the quarter.
InnoCare Pharma Stock Performance
INCPF opened at $1.55 on Friday. InnoCare Pharma has a twelve month low of $1.55 and a twelve month high of $2.31. The company has a fifty day moving average of $1.55 and a 200-day moving average of $1.60.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, InnoCare Pharma presently has a consensus rating of “Buy”.
InnoCare Pharma Company Profile
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Stories
- Five stocks we like better than InnoCare Pharma
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
